

# THE *EMPAGRAN* EXCEPTION: BETWEEN *ILLINOIS BRICK* AND A HARD PLACE

Victor P. Goldberg\*

I.	Introduction.....	785
II.	<i>Empagran</i> and the FTAIA.....	787
III.	What's <i>Illinois Brick</i> Got to Do with It?.....	794
IV.	Concluding Remarks.....	800

## I. INTRODUCTION

Before it was uncovered and prosecuted, the international vitamin cartel, known as “Vitamins, Inc.” by its perpetrators, was extraordinarily successful. Estimates of cartel profits run as high as \$18 billion (in 2003 dollars).<sup>1</sup> In addition to substantial criminal sanctions, cartel members paid over \$2 billion to American plaintiffs.<sup>2</sup> When foreign plaintiffs tried to sue the foreign defendants in American courts, however, they encountered resistance.<sup>3</sup> A trial court read the Foreign Trade Antitrust Improvements Act (“FTAIA”)<sup>4</sup> to restrict the

---

\* Jerome L. Greene Professor of Transactional Law at Columbia University School of Law. I would like to thank Benjamin Brickner for his assistance.

<sup>1</sup> Brief for Certain Professors of Economics as Amici Curiae in Support of Respondents at 10, *F. Hoffmann–La Roche Ltd. v. Empagran S.A.*, 542 U.S. 155 (2004) (No. 03-724) [hereinafter *Economists’ Brief*], 2004 WL 533930. For the story of the vitamin cartel, see David Barboza, *Tearing Down The Facade of ‘Vitamins Inc.’*, N.Y. TIMES, Oct. 10, 1999, at C1.

<sup>2</sup> Amici for the defendants reckoned the total financial antitrust fines and penalties imposed on the cartel were between \$4.4 and \$5.6 billion. Brief Amici Curiae of Professors Darren Bush et al. in Support of Respondents, at 15 n.5, *Empagran*, 542 U.S. 155 (No. 03-724), 2004 WL 533933.

<sup>3</sup> Plaintiffs included five foreign vitamin distributors located in Ukraine, Australia, Ecuador, and Panama. *Empagran*, 542 U.S. at 159.

<sup>4</sup> Foreign Trade Antitrust Improvements Act, Pub. L. No. 97-290, 96 Stat. 1233 (1982).

reach of the Sherman Act and preclude foreign purchasers from suing the foreign defendants.<sup>5</sup> The D.C. Circuit reversed, holding that the facts brought the case within FTAIA's exceptions.<sup>6</sup> There already being a circuit split,<sup>7</sup> the Supreme Court granted certiorari. In its unanimous decision, the Court ruled that the FTAIA exception did not apply where a claim rested solely on foreign harm that was independent of any adverse domestic effect.<sup>8</sup>

The FTAIA excludes most anti-competitive foreign trade and commercial activity from the Sherman Act's reach. However, the Act carves out an exception to this general rule, though the parameters of the exception are less than clear:

[The Sherman Act] shall not apply to conduct involving trade or commerce (other than import trade or import commerce) with foreign nations unless—

(1) such conduct has a direct, substantial, and reasonably foreseeable effect—

(A) on trade or commerce which is not trade or commerce with foreign nations, or on import trade or import commerce with foreign nations . . . and

(2) such effect gives rise to a claim under the provisions of [the Sherman Act].<sup>9</sup>

---

<sup>5</sup> *Empagran S.A. v. F. Hoffmann-La Roche, Ltd.*, No. Civ. 001686 (TFH), 2001 WL 761360, at \*4 (D.D.C. June 7, 2001).

<sup>6</sup> *Empagran S.A. v. F. Hoffmann-La Roche, Ltd.*, 315 F.3d 338, 350 (D.C. Cir. 2003).

<sup>7</sup> Compare *Kruman v. Christie's Int'l*, 284 F.3d 384 (2d Cir. 2002) (holding that foreign plaintiffs could sue), with *Den Norske Stats Oljeselskap As v. HeereMac Vof*, 241 F.3d 420 (5th Cir. 2001) (dismissing foreign plaintiff's claim for lack of subject matter jurisdiction).

<sup>8</sup> *F. Hoffmann-La Roche Ltd. v. Empagran S.A.*, 542 U.S. 155, 159 (2004). Justice O'Connor did not participate; Justice Scalia filed a very short concurring opinion, in which Justice Thomas joined.

<sup>9</sup> Foreign Trade Antitrust Improvements Act, Pub. L. No. 97-290, 96 Stat. 1246 (1982).

Plaintiffs argued that their claim fell within that exception, but the Court held otherwise. It remanded the case for consideration of an alternative theory that plaintiffs had proffered, but on which the D.C. Circuit had not ruled. The Supreme Court thereby left future foreign plaintiffs with some wiggle room, but little guidance.<sup>10</sup> On remand, the D.C. Circuit rejected this alternative theory.<sup>11</sup> Subsequent plaintiffs have fared similarly, with only one reported decision of a suit (involving price fixing of computer components) surviving a motion to dismiss.<sup>12</sup>

In *Empagran*, the Court recognized that the cartel's domestic price fixing could only be sustained if it operated both domestically and abroad; nonetheless, it held that this would be insufficient to allow foreign plaintiffs to sue foreign sellers in the U.S. If not then, do any circumstances fall within the FTAIA exception?

In this article, I identify one narrow class of cases that would satisfy the statutory exception. I must emphasize the modest scope of this inquiry. I am not suggesting that this is a socially optimal policy, or, indeed, even a wise one. Instead of focusing on the interrelatedness of the foreign and domestic prices, the inquiry centers on the resale of goods to the domestic market. The argument, hinted at by Justice Scalia at oral argument, is a variant on *Illinois Brick Co. v. Illinois*, the Supreme Court's landmark ruling rejecting a passing-on theory of injury suffered by indirect purchasers.<sup>13</sup> Before developing this argument in Section III, I first briefly detail the *Empagran* decisions.

## II. EMPAGRAN AND THE FTAIA

During the *Empagran* litigation, it was undisputed that the domestic and foreign vitamin markets were

---

<sup>10</sup> *Empagran*, 542 U.S. at 175.

<sup>11</sup> *Empagran S.A. v. F. Hoffmann–La Roche, Ltd.*, 417 F.3d 1267 (D.C. Cir. 2005).

<sup>12</sup> *Sun Microsystems Inc. v. Hynix Semiconductor Inc.*, 534 F. Supp. 2d 1101 (N.D. Cal. 2007).

<sup>13</sup> *Illinois Brick Co. v. Illinois*, 431 U.S. 720 (1977).

interrelated.<sup>14</sup> Vitamins, Inc. could neither operate solely within the U.S. while leaving foreign markets competitive, nor cartelize foreign markets alone.<sup>15</sup> Transportation costs were minimal, trade barriers were low, and vitamins were fungible. Had the conspiracy been confined to a single geographic submarket, it would have been doomed by arbitrage. The plaintiffs argued, and the D.C. Circuit on its initial hearing of the case agreed, that this interrelationship was sufficient to bring the cartel within the FTAIA exception.<sup>16</sup> The conspiracy itself had (1) “a direct, substantial, and reasonably foreseeable effect” on domestic competition, and (2) this effect (injury to the domestic customer) “[gave] rise to” a Sherman Act claim.<sup>17</sup>

Although the Supreme Court accepted the interrelationship argument, its framing of the issue made clear that this was insufficient to find an FTAIA exception:

The price fixing conduct significantly and adversely affects both customers outside the United States and customers within the United States, but the adverse foreign effect is *independent of* any adverse domestic effect. In these circumstances, we find that the

---

<sup>14</sup> At oral argument, plaintiff's counsel asserted:

“Now, the reason our position is critical is the one identified by Justice Kennedy, and that is that the conspirators' cartel encompassed a worldwide market for bulk vitamins and the worldwide market is relevant because geographic boundaries don't have any meaning here. A conspiracy limited to U.S. commerce would have collapsed as U.S. purchasers bought abroad, as Justice Scalia has said.”

Transcript of Oral Argument at 19, *F. Hoffmann–La Roche Ltd. v. Empagran S.A.*, 542 U.S. 155 (2004) (No. 03-724), 2004 WL 1047902, 41 U.S.L.W. 3686.

<sup>15</sup> Like love and marriage or a horse and carriage, you can't have one without the other. See SAMMY CAHN AND JIMMY VAN HEUSEN, *LOVE AND MARRIAGE* (1958).

<sup>16</sup> *Empagran S.A. v. F. Hoffmann–La Roche, Ltd.*, 315 F.3d 338, 340 (D.C. Cir. 2003) (quoting 15 U.S.C. § 6a(1) (2006)).

<sup>17</sup> *Id.*

FTAIA exception does not apply (and thus the Sherman Act does not apply).<sup>18</sup>

The Court's primary justification for this conclusion was prescriptive comity, a rule of construction that "cautions courts to assume that legislators take account of the legitimate sovereign interests of other nations when they write American laws."<sup>19</sup> Thus, American law should not be read to supplant the laws of Canada, Japan, or other sovereign states when these nations are better able to determine the appropriate level of protection for their domestic customers from anticompetitive conduct.<sup>20</sup> When the plaintiffs argued that there could be no conflict of law because all governments agreed that naked price fixing was bad, the Court was not persuaded: "[S]everal foreign nations have filed briefs here arguing that to apply our remedies would unjustifiably permit their citizens to bypass their own less generous remedial schemes, thereby upsetting a balance of competing considerations that their own domestic antitrust laws embody."<sup>21</sup>

---

<sup>18</sup> *Empagran*, 542 U.S. at 164 (emphasis added).

<sup>19</sup> *Id.* at 164–65. The majority's second argument was based on its understanding of the legislative history of the FTAIA. *Id.* at 162–63.

<sup>20</sup> *Id.* at 165. Amicus Briefs were filed on behalf of the defendants by seven foreign governments: Germany, Belgium, Canada, Japan, the United Kingdom, Ireland and the Netherlands. Brief of the Governments of the Federal Republic of Germany and Belgium as Amici Curiae in Support of Petitioners, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 226388 [hereinafter Germany and Belgium Brief]; Brief for the Government of Canada as Amicus Curiae Supporting Reversal, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 226389 [hereinafter Canada Brief]; Brief of the Government of Japan as Amicus Curiae in Support of Petitioners, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 226390 [hereinafter Japan Brief]; Brief of the United Kingdom of Great Britain and Northern Ireland, Ireland and the Kingdom of the Netherlands as Amici Curiae in Support of Petitioners, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 226597 [hereinafter United Kingdom and Netherlands Brief].

<sup>21</sup> *Empagran*, 542 U.S. at 167. These nations' remedies varied widely, with American treble damages plus attorney fees falling near the top of the remedial scale. See e.g., Germany and Belgium Brief, *supra* note 20; Canada Brief, *supra* note 20; Japan Brief, *supra* note 20.

Plaintiffs enlisted a gaggle of economists to argue that allowing only domestic victims to file suit against an international cartel with a worldwide market would result in under-deterrence.<sup>22</sup> Defendants did not address this argument directly; instead defendants emphasized that the deterrence mix is multifaceted because it includes American private treble-damages suits, American criminal prosecutions, and foreign enforcement actions.<sup>23</sup> The defendants and several amici argued, somewhat counter-intuitively, that increasing potential liability by permitting foreign plaintiffs to sue could actually *reduce* deterrence.<sup>24</sup> Because an important element of the Department of Justice's antitrust detection strategy is amnesty, a cartel member could see a reduction or elimination of its public penalty in return for cooperating with law enforcement officials.<sup>25</sup> The benefits of cooperation, however, are diluted as exposure to private damages increases. Broadening civil exposure to

---

<sup>22</sup> See e.g., Economists' Brief, *supra* note 1; Brief of Amici Curiae Economists Joseph E. Stiglitz and Peter R. Orszag in Support of Respondents, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 533934; Brief Amici Curiae of Professors Darren Bush et al. in Support of Respondents, *Empagran*, 524 U.S. 155 (No. 03-724), 2004 WL 533933.

<sup>23</sup> *Empagran*, 542 U.S. at 167-74. If under-deterrence were indeed a concern, Congress could address this without permitting foreign claims by boosting penalties in the two domestic categories.

<sup>24</sup> Brief for the United States as Amicus Curiae Supporting Petitioners at 17, *Empagran*, 542 U.S. 155 (No. 03-724), 2004 WL 234125; United Kingdom Brief, *supra* note 20, at 9-14.

<sup>25</sup> At oral argument, R. Hewitt Pate, Asst. Att'y Gen., as amicus curiae in support of petitioners testified that,

[g]iven the key role of deterrence, both in the opinion below and in the respondents' arguments here, the United States thinks it important to offer the Court an accurate understanding of how international cartel enforcement really works. It's only in the past 8 years that we've begun to see dramatic success in detecting and punishing international cartels, and that has come about only by international co-operation with other enforcement agencies and through the use of amnesty programs.

include foreign plaintiffs, the defendants argued, would undermine the amnesty program and weaken deterrence. The Court acknowledged the disagreement, but declined to choose sides.<sup>26</sup>

Not surprisingly, nations disagree as to the appropriate level of deterrence for anticompetitive activities. For international cartels, no country can determine the level of deterrence unilaterally; the policies of one nation will affect the policies of others. Even if we knew the optimal level of deterrence, the U.S. could not achieve that level without coordination with the rest of the world. As the Court observed:

No one denies that America's antitrust laws, when applied to foreign conduct, can interfere with a foreign nation's ability independently to regulate its own commercial affairs. But our courts have long held that application of our antitrust laws to foreign anticompetitive conduct is nonetheless reasonable, and hence consistent with principles of prescriptive comity, insofar as they reflect a legislative effort to redress *domestic* antitrust injury that foreign anticompetitive conduct has caused.<sup>27</sup>

---

<sup>26</sup> [R]espondents point to policy considerations, namely, that application of the Sherman Act in present circumstances will (through increased deterrence) help protect Americans against foreign-caused anticompetitive injury. Petitioners, however, have made important experience-backed arguments (based upon amnesty-seeking incentives) to the contrary. We cannot say whether, on balance, respondents' side of this empirically based argument or the enforcement agencies' side is correct.

*Empagran*, 542 U.S. at 174. Congress recently enacted legislation limiting the damage remedy to single damages for those granted amnesty. Antitrust Criminal Penalty Enhancement and Reform Act, Pub. L. No. 108-237, 118 Stat. 665 (2004). The European Commission has also recommended limiting damages for firms applying for leniency. Comm'n of the European Communities, *White Paper on Damages for Breach of the EC Antitrust Rules* (2008).

<sup>27</sup> *Empagran*, 542 U.S. at 165.

The Court concluded, it would not be “reasonable to apply those laws to foreign conduct *insofar as that conduct causes independent foreign harm and that foreign harm alone gives rise to the plaintiff’s claim.*”<sup>28</sup> When the adverse foreign effect is “independent of any adverse domestic effect,” the FTAIA would bar the plaintiffs.<sup>29</sup> Although the Court in *Empagran* determined that the foreign effect of Vitamins, Inc. was independent of its domestic effect, removing the plaintiffs’ claim from FTAIA’s limited exception (and thus from the Sherman Act as well), a ray of hope remained for the plaintiffs. On appeal before the D.C. Circuit, the plaintiffs had presented two theories of their case, only one of which the Court of Appeals had addressed.<sup>30</sup> For this reason, the Supreme Court remanded so that the plaintiffs could present their alternative theory:

Respondents contend that, because vitamins are fungible and readily transportable, without an adverse domestic effect (*i.e.*, higher prices in the United States), the sellers could not have maintained their international price-fixing arrangement and respondents would not have suffered their foreign injury. They add that this “but for” condition is sufficient to bring the price-fixing conduct within the scope of the FTAIA’s exception.<sup>31</sup>

Instead of simply stating that for the cartel to succeed, prices would have to be fixed in both the foreign and domestic markets, plaintiffs argued that high domestic prices caused foreign prices to be high, thereby causing antitrust injury. On remand, the Court of Appeals rejected this argument, concluding that “but for” causation was

---

<sup>28</sup> *Id.*

<sup>29</sup> *Id.* at 164.

<sup>30</sup> *Empagran S.A. v. F. Hoffmann–La Roche, Ltd.*, 315 F.3d 338, 341 (D.C. Cir. 2003) (“In light of our disposition in favor of appellant on other grounds, we find it unnecessary to address this ‘alternative’ theory of subject matter jurisdiction.”).

<sup>31</sup> *Empagran*, 542 U.S. at 175.



insufficient.<sup>32</sup> The domestic injury needed to be a *proximate cause* of the foreign plaintiffs' injury: "The statutory language—'gives rise to'—indicates a direct causal relationship, that is, proximate causation, and is not satisfied by the mere but-for 'nexus.'"<sup>33</sup>

The strained causality argument was a response to the Supreme Court's rejection of the notion that the interrelation of the foreign and domestic markets would be enough for the plaintiffs to prevail.<sup>34</sup> The "but for" versus "proximate" cause characterization doesn't really help. As Judge Noonan observed in a concurring opinion post-*Empagran*, "[w]e reach this . . . point not from guidance in words like 'proximate' or 'direct' but from a strong sense that the protection of consumers in another country is normally the business of that country. Location, not logic, keeps [Plaintiffs'] claim out of court."<sup>35</sup>

The simple economic point is that for the Vitamins, Inc. conspirators to maintain a cartel price *anywhere*, they had to maintain it *everywhere*. Domestic price fixing, without more, would not cause foreign injuries; likewise, foreign price fixing, without more, would not cause domestic injuries. The *Empagran* plaintiffs sought to argue that domestic price fixing had a substantial effect on domestic competition (true); gave rise to an antitrust claim (also true); was not sustainable without prices being fixed in the foreign markets (also true); and therefore the foreign plaintiffs could sue.

On remand, the Court of Appeals found that the causation was indirect. "It was the foreign effects of price-fixing outside of the United States that directly caused, or 'g[a]ve rise to,' their losses when they purchased vitamins

---

<sup>32</sup> *Empagran S.A. v. F. Hoffmann–La Roche, Ltd.*, 417 F.3d 1267, 1270 (D.C. Cir. 2005).

<sup>33</sup> *Id.* at 1271.

<sup>34</sup> Plaintiffs felt precluded from making a more natural causation argument: high foreign prices caused, or at least enabled, domestic prices to be high.

<sup>35</sup> *In re Dynamic Random Access Memory (DRAM) Antitrust Litig.*, 546 F.3d 981, 991 (9th Cir. 2008) (Noonan, J., concurring).

abroad at super-competitive prices.”<sup>36</sup> Therefore, the court concluded, the plaintiffs “[did] not establish . . . that the U.S. effects of the appellees’ conduct—i.e., increased prices in the United States—proximately caused the foreign appellants’ injuries.”<sup>37</sup>

### III. WHAT’S *ILLINOIS BRICK* GOT TO DO WITH IT?

Under federal law, if cartel member X sells to Y, who then resells to Z, the direct purchaser (Y) can sue under the Sherman Act, but the indirect purchaser (Z) cannot. So decided the Supreme Court in *Hanover Shoe*<sup>38</sup> and *Illinois Brick*.<sup>39</sup> The direct purchaser can sue for the entire overcharge, regardless of whether it “passed on” any or all of it (*Hanover Shoe*)<sup>40</sup> and the indirect purchaser cannot sue (*Illinois Brick*).<sup>41</sup> A majority of states have adopted *Illinois Brick* repealers that permit suits by indirect purchasers.<sup>42</sup> At the federal level, there has been some movement to overrule *Illinois Brick*.<sup>43</sup> Given the inherent difficulty of determining the incidence of an overcharge, I think the federal bar against indirect purchasers’ suits is appropriate. In any event, the *Illinois Brick* rule was in place when *Empagran* was decided and remains the law.

---

<sup>36</sup> *Empagran*, 417 F.3d at 1271.

<sup>37</sup> *Id.*

<sup>38</sup> *Hanover Shoe v. United Shoe Mach. Corp.*, 392 U.S. 481 (1968).

<sup>39</sup> *Illinois Brick Co. v. Illinois*, 431 U.S. 720 (1977).

<sup>40</sup> *Hanover Shoe*, 392 U.S. at 494.

<sup>41</sup> *Illinois Brick*, 431 U.S. at 720.

<sup>42</sup> “At the present, more than thirty-five states permit indirect, as well as direct, purchasers to sue for damages under state law.” ANTITRUST MODERNIZATION COMMISSION, REPORT AND RECOMMENDATIONS 269 (2007), [http://govinfo.library.unt.edu/amc/report\\_recommendation/amc\\_final\\_report.pdf](http://govinfo.library.unt.edu/amc/report_recommendation/amc_final_report.pdf).

<sup>43</sup> *Id.* at 266. For criticism of the recommendation, see William H. Page, *Class Interpleader: The Antitrust Modernization Commission’s Recommendation to Overrule Illinois Brick Manuscript*, June 17, 2008, available at <http://ssrn.com/abstract=1147200>.

During oral argument in *Empagran*, Justice Scalia raised *Illinois Brick*.<sup>44</sup> In his questioning of respondent's counsel, he added a geographic component to the X-Y-Z hypothetical.<sup>45</sup> The foreign cartel member (X) sold to a domestic firm (Y) which then resold to a foreign plaintiff (Z):

I would think your defense against that is . . . not to assert that there's no effect on . . . foreign commerce, on our exports, because . . . I think there is . . . . I would think your defense is . . . in Section 2 of the Foreign Trade Antitrust Improvements Act, which requires that this effect on commerce, on export commerce, gives rise to a claim under the provisions of Sections 1 to 7, and . . . the only way it gives rise to a claim on the part of these people is a claim as second purchasers, and *Illinois Brick* would have excluded their claim, I assume, if they are re-buying . . . from people in the United States. Wouldn't that be the case?<sup>46</sup>

He raised *Illinois Brick* again when questioning one of the plaintiff's variations on the arbitrage/one market theme.<sup>47</sup> Plaintiff argued that if there had not been price fixing in the United States, the foreign buyers would have purchased from the Americans at a lower price.<sup>48</sup> Since the American price fixing made that lower price unavailable, plaintiff argued, they were forced to pay a high foreign price. Justice Scalia responded:

[I]t seems extraordinary to me that if . . . a foreign company had been injured by buying drugs from an American company that bought them from the conspirators at an excessively high price, that foreign company would not have a cause of action. But you're saying that a foreign company has a cause of

---

<sup>44</sup> Transcript of Oral Argument at 8, *F. Hoffmann-La Roche Ltd. v. Empagran S.A.*, 542 U.S. 155 (2004) (No. 03-724), 2004 WL 1047902, 41 U.S.L.W. 3686.

<sup>45</sup> *Id.*

<sup>46</sup> *Id.*

<sup>47</sup> *Id.* at 35.

<sup>48</sup> *Id.* at 35-6.

action by reason of the fact that had the American company not purchased at the artificially high conspiratorial price, but at a lower price, they might have purchased . . . from that intermediate person . . . . [W]hereas *Illinois Brick* would clearly bar the first suit, you're saying it doesn't bar the second suit as a rationale for allowing them to sue here, and that strikes me as very strange.<sup>49</sup>

To rephrase his characterization of plaintiff's argument, if X (foreign producer) sold to Y (American) who resold to Z (foreign), Z loses under *Illinois Brick*; but if Z bought directly from X and merely complained about Y's price, then Z would be able to sue.

Neither the Supreme Court nor the Court of Appeals on remand followed up on Justice Scalia's invocation of *Illinois Brick*, which is mentioned in neither decision. Nonetheless, I believe that it is the key to finding at least one class of cases that would fall within the exception. To be clear, it is not that *Illinois Brick* provides the rationale; rather its role as a bar to certain domestic claimants is what matters. The FTAIA exception fills a void left by *Illinois Brick* when the direct purchaser is a foreign entity.

Consider another variation on the X-Y-Z hypothetical in which the locations of Y and Z in the Scalia hypothetical are reversed. A *foreign* conspirator (X) sells vitamins to a distributor (Y), who then sells those same vitamins to a *domestic* customer (Z). As before, *Illinois Brick* would preclude a suit by the indirect purchaser (Z). Would Y, the direct purchaser, have a claim? If Y were a domestic firm, *Illinois Brick* would clearly allow the suit. But what if Y were a *foreign* firm? There are three possibilities: (1) bar the foreign suit so that X is liable to neither Y nor Z; (2) maintain the foreign bar while carving an exception to *Illinois Brick* that allows Z to sue whenever the direct purchaser is barred from doing so (in general or specifically when the direct purchaser is a foreign entity); or (3) keep *Illinois Brick* intact and allow Y to sue. The last option is a

---

<sup>49</sup> *Id.* at 35.

natural reading of the FTAIA exception: the effect on domestic commerce (Z) is direct and reasonably foreseeable (more on “substantial” below) and the effect itself (an elevated domestic price) gives rise to a Sherman Act claim.

Suppose we add another step to the X-Y-Z hypothetical. Instead of selling vitamins directly to U.S. customers, the foreign direct purchaser (Y) adds the vitamins to pig feed and ultimately exports the pork to the United States.<sup>50</sup> Suppose further that the price of vitamins is an insignificant contributor to the cost of pork and that the exported quantity is too small to influence the American pork market. Thus, the impact of the overcharged vitamins would be confined to the economic rents of foreign producers. Could Y sue to recover the overcharge? It seems clear that this claim would falter before both clauses of the FTAIA exception. The conspiratorial overcharging might have a direct effect on some markets, but the effect on *domestic markets* would remain insubstantial (Clause 1).<sup>51</sup> Since domestic pork prices would not be affected, the overcharge would not give rise to a Sherman Act claim (Clause 2).<sup>52</sup> There are intermediate cases. Suppose instead that Y repackaged the vitamins and that the value added was ten percent; that might be able to pass the substantiality test. Where precisely the line should be drawn is something that courts would have to work out.

The FTAIA’s concern with “substantial” effects modifies the *Illinois Brick* rule when the direct purchaser is a foreign firm. If the direct purchaser were a domestic firm, the ultimate effect on final users would be irrelevant. Under *Hanover Shoe*, even if there were no impact on final users, a domestic direct purchaser could recover the entire overcharge (trebled). If the direct purchaser were foreign, however, liability would turn on both the likelihood that the

---

<sup>50</sup> One of the *Empagran* plaintiffs was the Winddridge Pig Farm of Australia. *Id.* at 7.

<sup>51</sup> See Foreign Trade Antitrust Improvements Act, 15 U.S.C. § 4013(a)(1) (2006).

<sup>52</sup> See *id.* at 4013(b).

overcharge would be passed on to domestic customers and its magnitude.

One might argue that only the portion of the overcharge passed on to domestic customers should be included in a damages award, but this would recreate the very obstacles *Illinois Brick* allowed us to avoid. I propose a new interpretation of the FTAIA exception consistent with the Supreme Court's opinion that incorporates a concern for international comity while eliminating the inherent difficulty of determining the incidence of an overcharge. This approach entails a two-step process in which liability is determined before damages are calculated. The "passing on" question arises only at the first stage, determining liability: was it likely that there would be a discernible effect on the domestic market (substantiality)? Only a claim passing this hurdle would proceed to the damages stage. Here, the foreign direct purchaser, like its domestic counterpart, would recover the full overcharge, but only on goods actually sold into the United States. If, for example, the foreign direct purchaser resold twenty percent of its purchased vitamins to the United States, it could recover the overcharge on those goods. The overcharge on the remaining 80 percent would not provide the basis for recovery since the effect on domestic commerce by the sale of those goods would be indirect and therefore barred.

This narrow exception is consistent with the FTAIA and the Supreme Court's interest in international comity. Foreign entities can sue only if the effect on the domestic price was direct and substantial—that is, only if a significant portion of the price increase was passed on to the domestic customers. For the most part, the interests of the foreign countries in maintaining their own remedy structures would be honored. Liability would be limited to the case in which the foreign sale resulted directly in a higher price to the eventual domestic customer.

This interpretation would not have benefited the *Empagran* plaintiffs, since it is doubtful that any of the vitamins they purchased would have ended up in the United States. The exception is a very narrow one. To illustrate the

limited nature of the exception I propose, consider *Den Norske*, one of the two opinions causing the pre-*Empagran* circuit split.<sup>53</sup> The Supreme Court's decision in *Empagran* ratified the rejection of *Den Norske*'s claim, though for reasons unrelated to the approach suggested here. *Den Norske*, a Norwegian oil firm, sued providers of heavy-lift barge services who had conspired to suppress and eliminate competition by rigging bids and allocating customers and territories. There were only six or seven such barges in the world, and there was no question that there was a global market. As in *Empagran*, the court recognized that the price paid by the foreign plaintiff was inflated, but that fact alone would not give rise to liability.<sup>54</sup>

The plaintiffs argued that the barges were an input in their production of offshore oil and that they sold a considerable amount of oil to the United States (roughly 400,000 barrels per day). The conspiracy, they claimed, "compelled Americans to pay supra-competitive prices for oil."<sup>55</sup> Under the approach suggested here, the first stage of the inquiry asks whether the overcharge for Norwegian barge services substantially impacted U.S. oil prices. If so, the second stage would determine damages based on the overcharge for barge services, not for the amount passed on to American consumers by inflated domestic oil prices. Further, the overcharge would be assessed not for all the barge services, but only for that fraction equal to the portion of the oil sold by the plaintiff into the United States. In *Den Norske*, the numerator would be 400,000 barrels per day (the decision does not provide information on the denominator).<sup>56</sup>

Would *Den Norske*'s claim survive the first step? Almost certainly not. Norwegian oil production forms but a sliver of the international oil market. Any increase in the cost of producing Norwegian oil is unlikely to have any impact on international oil prices generally and, therefore, U.S.

---

<sup>53</sup> *Den Norske Stats Oljeselskap As v. HeereMac Vof*, 241 F.3d 420 (5th Cir. 2001).

<sup>54</sup> *Id.* at 426–28.

<sup>55</sup> *Id.* at 426.

<sup>56</sup> *Id.* at 422.

domestic prices in particular. The effect would instead fall entirely on Norwegian economic rents. Thus, a court should hold that the claim fails to clear the first hurdle. A domestic purchaser of barge services, however, would be able to recover for the full overcharge, even though the price of oil was unaffected by the conspiracy.

Under the suggested approach, Den Norske's claim would be dismissed from a U.S. court for want of a substantial effect on domestic commerce or trade. If, on the other hand, the conspiracy had a substantial effect, then damages would be proportional to Den Norske's sales into the United States. In either case, Den Norske would have recourse against the conspiratorial barge companies in Norwegian (or other foreign) courts for the impact on non-U.S. markets.

#### IV. CONCLUDING REMARKS

There are a number of markets like the vitamin market in which domestic and international markets are tightly linked by arbitrage. An international cartel could not successfully fix prices in the domestic market without also fixing prices in the foreign market, and vice versa. That is the simple truth that formed the basis of the plaintiffs' claims in *Empagran*. In their interpretation of the FTAIA, the Supreme Court and the D.C. Court of Appeals acknowledged that truth, but concluded that it did not bring the plaintiffs within the FTAIA exception.

Building on arguments raised by Justice Scalia at oral argument, I have offered a simple—and very narrow—interpretation of the FTAIA exception. It fills the gap created by *Illinois Brick* when the direct purchaser is a foreign entity and the domestic indirect purchasers face elevated prices. Domestic effects do not bring about foreign injury, as plaintiffs argue. Rather, domestic effects arise only if a substantial portion of the overcharge to foreign firms is passed on to their domestic customers. It should be clear that the foreign defendant's exposure would be much less under this interpretation compared to the potential liability under the one market/arbitrage theories proposed by



the *Empagran* plaintiffs. With this interpretation, most foreign claims against foreigners would be barred.

The FTAIA, under this interpretation, provides some possibility of relief while respecting a concern for international comity. It would limit the foreign direct purchaser's claims to those that have a substantial effect on the domestic market—that is, where a substantial portion of the overcharge is passed on to the domestic market. If the foreign purchaser bore most of the overcharge, its claim would properly fall within the scope of foreign governments' competition policy, not that of the United States. If, on the other hand, the foreign purchaser resold a substantial portion of the overpriced goods to the domestic marketplace, causing a direct effect on domestic trade, the purchaser ought to have recourse in an American court.